Wolk DA, et al. - In this multicenter cohort study, the researchers assessed the ability of flutemetamol F 18 and other biomarkers to evaluate the risk of progression from amnestic mild cognitive impairment (aMCI) to probable Alzheimer disease (AD). Patients with aMCI underwent positron emission tomography (PET) at baseline followed by local clinical assessments every 6 months for up to 3 years from November 11, 2009, to January 16, 2014, in this investigation. The data presented in this work showed a combination of positive results of flutemetamol F 18–labeled PET, low hippocampal volume, and cognitive status corresponded with a high likelihood of risk of progression from aMCI to probable AD within 36 months.